VEXAS, Chediak–Higashi syndrome and Danon disease: myeloid cell endo-lysosomal pathway dysfunction as a common denominator? by Coline Savy, Maxence Bourgoin, Thomas Cluzeau, Arnaud Jacquel, Guillaume Robert, Patrick Auberger

Get full text

FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the... by Pierre Peterlin, Joëlle Gaschet, Pascal Turlure, Marie-Pierre Gourin, Pierre-Yves Dumas, Sylvain Thepot, Ana Berceanu, Sophie Park, Marie-Anne Hospital, Thomas Cluzeau, Jose-Miguel Torregrosa-Diaz, Louis Drevon, Rosa Sapena, Fatiha Chermat, Lionel Ades, Sophie Dimicoli-Salazar, Maxime Jullien, Pierre Fenaux, Patrice Chevallier.

Get full text

Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS by Thomas Cluzeau, Fabio Guolo, Edmond Chiche, Paola Minetto, Ramy Rahme, Sarah Bertoli, Luana Fianchi, Jean-Baptiste Micol, Michele Gottardi, Pierre Peterlin, Sara Galimberti, Xavier Thomas, Giuliana Rizzuto, Olivier Legrand, Michela Rondoni, Emmanuel Raffoux, Giambattista Bertani, Alexis Caulier, Michelina D’Argenio, Caroline Bonmati, Atto Billio, Caroline Lejeune, Barbara Scappini, Arnaud Pigneux, Patrizia Zappasodi, Christan Recher, Francesco Grimaldi, Lionel Ades, Roberto M. Lemoli

Get full text

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML by David A. Sallman, Rami S. Komrokji, Amy E. Dezern, Marie Sebert, Guillermo Garcia‐Manero, Ramy Rahmé, Eric S. Winer, Jacqueline Lehmann‐Che, Gail J. Roboz, Isabelle Madelaine, Mikkael A. Sekeres, Pierre Peterlin, Onyee Chan, Odile Beyne‐Rauzy, Andrew Kuykendall, Christian Recher, Amy McLemore, Aspasia Stamatoullas, Ling Zhang, Lise Willems, Qianxing Mo, Emmanuel Raffoux, Lisa Nardelli, Céline Berthon, Najla H. Al Ali, Bruno Quesnel, Eric Padron, Hagop M. Kantarjian, Alan F. List, Lionel Ades, Jeffrey E. Lancet, Pierre Fenaux, Thomas Cluzeau

Get full text

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS by Amy E. DeZern, Sylvain Thepot, Stephane de Botton, Andrea Patriarca, Dries Deeren, Jose-Miguel Torregrossa-Diaz, Giovanni Marconi, Teresa Bernal, Juan Bergua Burgues, Blanca Xicoy, Anna Jonášová, Amer M. Zeidan, Sophie Dimicoli-Salazar, Célestine Simand, David Valcarcel, Maria Diez Campelo, Wanxing Chai-Ho, Lalit Saini, Alice Garnier, Klaus Geissler, Yishai Ofran, Zsolt Nagy, Pramila Krishnamurthy, Michael Lübbert, Grzegorz Basak, Hetty E. Carraway, David A. Sallman, Uma Borate, Valeria Santini, Victoria Campbell, Pierre Fenaux, Thorsten Braun, Francesco Lanza, Jan Maciej Zaucha, David A. Roth, Sofia Paul, Pourab Roy, Michael J. Kelly, Angela Volkert, Jaime Chisholm, Tanya Abdul Malak, Virginia M. Klimek, Thomas Cluzeau

Get full text